RESEARCH · BPC-157 + TB-500 · PHARMACOKINETICS AND METABOLITES
BPC-157 and TB-500 Pharmacokinetics: Half-Life, Metabolites, Detection Methods and Sample Stability
PurixLab’s BPC-157 + TB-500 10mg vial combines two research peptides: BPC-157, the 15-amino-acid sequence GEPPPGKPADDAGLV, and TB-500, a synthetic peptide built around the acetylated LKKTETQ region of thymosin beta-4 (Tβ4). Our earlier articles cover the blend composition, the molecular mechanisms and the human data gap. This article asks a more basic question: what happens to each peptide after it enters a living system, and how do analytical laboratories find it and its breakdown products? These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Why pharmacokinetics matters for these peptides
Small linear peptides are usually cut quickly by proteases in blood, liver and kidney. For BPC-157 and TB-500 the record is thin: one formal animal ADME study for BPC-157, a set of metabolism and detection papers for TB-500, and almost no human pharmacokinetic data for either.
BPC-157: the first formal ADME study
A 2022 study in rats and beagle dogs is the only formal pharmacokinetic, distribution, metabolism and excretion study of BPC-157 we found [1]. After single intravenous and intramuscular administration, and after repeated intramuscular administration:
- Short half-life. The elimination half-life of the intact peptide was less than 30 min, and exposure rose linearly with the amount given in both species [1].
- Species differences. Mean absolute bioavailability after intramuscular administration was approximately 14%-19% in rats and 45%-51% in beagle dogs [1].
- Fate of the peptide. Using tritium-labelled BPC-157, the authors found that the peptide was rapidly broken into small fragments and then single amino acids, and that urine and bile were the main excretory routes [1].
A 2026 review of BPC-157 from a drug-development standpoint calls this a pharmacokinetic-pharmacodynamic disconnect: a plasma half-life under 30 min sits alongside biological effects reported to last hours to days in preclinical models [2]. The same review notes that no pharmaceutical-grade formulation has been validated and that available clinical data come from fewer than 30 subjects across three uncontrolled pilot studies [2].
Human data for BPC-157: two people
The only human safety study with intravenous BPC-157 we found enrolled 2 participants at a private clinic, both of whom had used the peptide before. Blood work and vital signs on three consecutive days showed no measurable changes in the tested heart, liver, kidney, thyroid or glucose markers, and no side effects were reported [3]. With two participants, no control group and no plasma concentrations reported, the study says little about human pharmacokinetics.
BPC-157 metabolism in the laboratory
- A stable metabolite. Anti-doping researchers identified BPC-157 in confiscated vials and found in plasma incubations that it forms a stable metabolite expected to be detectable in urine. Their validated urine method had a limit of detection of 0.1 ng/mL, and BPC-157 was stable in urine for at least 4 days [4].
- Isotope-labelled tracing. Using 13C/15N-labelled BPC-157 and high-resolution mass spectrometry, a 2023 study found one metabolite from a previously undescribed pathway plus eight from ordinary amide-bond cleavage, and validated a human urine method for the parent and five main metabolites with detection limits of 0.01~0.11 ng/mL [5].
TB-500: what is actually in the vial
When anti-doping chemists analysed a product sold as TB-500, they identified the N-terminally acetylated 17-23 fragment of human Tβ4, Ac-LKKTETQ, confirmed it by synthesis and proposed detection strategies for plasma and urine [6]. The LKKTETQ segment is the region of Tβ4 linked to actin binding and cell migration, and the acetyl group is artificial [7]. TB-500 is therefore not the full Tβ4 protein, and data for one do not automatically apply to the other.
TB-500 metabolites and detection
- Horses. A method for equine urine and plasma detected the acetylated peptide at 0.02 ng/mL in plasma and 0.01 ng/mL in urine, and confirmed the peptide and its metabolites in samples from horses after a single administration of a TB-500 product [7].
- In vitro models compared. TB-500 was extensively metabolised by human kidney microsomes and liver S9 fraction, with cleavage at all peptide bonds despite protective modifications; human serum produced fewer metabolites [8]. A separate comparison found endopeptidase and exopeptidase activity in liver microsomes, S9 fraction and serum, with no significant difference between liver and kidney models [9].
- Rats and an active fragment. In rats, Ac-LK was the main metabolite in the first 0-6 h and Ac-LKK was detected up to 72 hr. None of the compounds was cytotoxic to fibroblasts, but only the metabolite Ac-LKKTE showed significant wound-healing activity, leading the authors to suggest that earlier reported TB-500 activity may come from this fragment rather than the parent [10].
Full-length thymosin beta-4: metabolites and a human trial
For the full protein, Ac-Tβ1-14 was proposed as a urinary biomarker: it appeared in several enzyme and cell systems and in the urine of treated rats, was quantified up to 48 h, and was absent from untreated controls and blank human urine [11]. Measurement is complicated because Tβ4 is abundant inside cells: in racing horses, plasma Tβ4 rose significantly and rapidly at 4°C when plasma was not separated from blood cells, although a non-natural synthesis impurity made exogenous material detectable [12]. A first-in-human phase I trial of recombinant Tβ4 enrolled 54 healthy subjects in a single-administration study and 30 in a 10-day study; adverse events were mild to moderate, exposure rose with the amount given, and there was no obvious accumulation [13]. That trial used the full recombinant protein, not TB-500.
Sample stability and the market
A 2026 blood-matrix workflow covering 54 prohibited compounds found that BPC-157 and TB500 degraded completely in serum, but not plasma, at 4 and 22 °C over one week, while all compounds remained detectable in dried blood spots [14]. Monitoring of 337 black-market products in Germany identified thymosin β4 among the notable findings [15], and a review of anti-doping methods lists TB-500 among the small peptides now targeted [16].
Reading this evidence critically
- One ADME study. The BPC-157 pharmacokinetic profile rests on a single rat and dog study [1,2].
- Detection is not pharmacology. Most metabolism papers were designed to find a marker for doping control, not to describe exposure or activity [4,5,8].
- Peptide versus protein. TB-500 fragment data and full-length Tβ4 data come from different molecules [6,13].
What remains open
- No study we found measured BPC-157 and TB-500 together, so possible interactions in metabolism are unknown.
- Human pharmacokinetic data for BPC-157 and for TB-500 are essentially absent.
- Whether active fragments such as Ac-LKKTE explain effects attributed to the parent peptides needs testing.
BPC-157 + TB-500 10mg at PurixLab
BPC-157 + TB-500 10mg: a labelled lyophilized research vial with BPC-157 5mg + TB-500 5mg per vial (10mg total), C$89 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PubMed 36588717 · PMC9794587 · doi:10.3389/fphar.2022.1026182
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. PubMed 42198317 · PMC13210877 · doi:10.3390/pharmaceutics18050625
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PubMed 40131143
- Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498. PubMed 28035768 · doi:10.1002/dta.2152
- Tian T, Jing J, Li Y, et al. Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS. Molecules. 2023;28(21):7345. PubMed 37959764 · PMC10650108 · doi:10.3390/molecules28217345
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823 · doi:10.1016/j.chroma.2012.09.043
- Zvereva I, Semenistaya E, Krotov G, et al. Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: Proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction. J Proteomics. 2016;149:85-97. PubMed 27569051 · doi:10.1016/j.jprot.2016.08.016
- Esposito S, Deventer K, Geldof L, et al. In vitro models for metabolic studies of small peptide hormones in sport drug testing. J Pept Sci. 2015;21(1):1-9. PubMed 25469748 · doi:10.1002/psc.2710
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. PubMed 38382158 · doi:10.1016/j.jchromb.2024.124033
- Rahaman KA, Muresan AR, Hasan ML, et al. Detection and quantification of the metabolite Ac-Tβ1-14 in in vitro experiments and urine of rats treated with Ac-Tβ4: A potential biomarker of Ac-Tβ4 for doping tests. Drug Test Anal. 2023;15(11-12):1454-1467. PubMed 37515313 · doi:10.1002/dta.3552
- Delcourt V, Garcia P, Chabot B, et al. Equine Doping Controls of Thymosin β 4: A Population Study and Strategy for Misuse Detection. Drug Test Anal. 2025;17(7):1071-1077. PubMed 39314109 · doi:10.1002/dta.3806
- Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. PubMed 34346165 · PMC8419156 · doi:10.1111/jcmm.16693
- Mazzarino M, Colpaert T, Deventer K, et al. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. Analyst. 2026;151(15):4398-4413. PubMed 42328738 · doi:10.1039/d6an00455e
- Krug O, Thomas A, Walpurgis K, et al. Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol. 2014;70(11):1303-11. PubMed 25168622 · doi:10.1007/s00228-014-1743-5
- Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Rev Proteomics. 2014;11(6):663-73. PubMed 25382550 · doi:10.1586/14789450.2014.965159